Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)
Australasian Journal of Dermatology2022Vol. 63(3), pp. 303–311
Citations Over Time
Peter Foley, Nicholas Manuelpillai, Con Dolianitis, Geoffrey D. Cains, Eric Mate, Rebecca Tronnberg, Christopher Baker
Abstract
Secukinumab demonstrated high drug survival and sustained effectiveness in Australian real-world setting, in biologic-naïve and biologic-experienced patients with severe CPP.
Related Papers
- → Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept(2017)33 cited
- → Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study(2022)7 cited
- → Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors(2018)1 cited
- → Cost-utility of secukinumab in Italian patients with moderate to severe plaque-type psoriasis(2017)
- → Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis(2020)